All In Biotech

Drug Trial Radar · NCT06716879

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

A Single-Center, Randomized, Investigator- and Participant-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics After a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Dec 6, 2024

Primary completion

Apr 4, 2025

Study completion Apr 4, 2025

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic parameters of 2 dose strengths of donzakimig, each administered subcutaneously as a single dose, in healthy Chinese and Japanese study participants.

Conditions

  • Healthy Participants

Interventions

  • DonzakimigDrug

    Drug: Donzakimig Pharmaceutical form: Subcutaneous solution

  • PlaceboDrug

    Drug: Placebo Pharmaceutical form: Subcutaneous solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of treatment-emergent adverse events (TEAEs)Time frame: From Baseline to End of Study visit (up to Day 57)
  2. Occurrence of serious treatment-emergent adverse events (serious TEAEs)Time frame: From Baseline to End of Study visit (up to Day 57)
  3. Maximum plasma concentration (Cmax) of donzakimigTime frame: Sampling timepoints will be on Day 1 (D1): at predose and 6 hours (h), 24h (D2), 72h (D4), 120h (D6), D8, D15, D22, D36, and D57 after investigational medicinal product (IMP) administration.
  4. Area under the plasma concentration-time curve from time 0 to t of donzakimigTime frame: Sampling timepoints will be on Day 1 (D1): at predose and 6 hours (h), 24h (D2), 72h (D4), 120h (D6), D8, D15, D22, D36, and D57 after investigational medicinal product (IMP) administration.
  5. Area under the plasma concentration-time curve from zero to infinity of donzakimigTime frame: Sampling timepoints will be on Day 1 (D1): at predose and 6 hours (h), 24h (D2), 72h (D4), 120h (D6), D8, D15, D22, D36, and D57 after investigational medicinal product (IMP) administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UP0142 1

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.